Segment, Geographic and Other Revenue Information (Parenthetical) (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2013		Apr. 01, 2012
Segment Reporting Information [Line Items]
Certain legal matters, net	$ (83)	[1]	$ 814	[1]
Certain asset impairment charges	399	[2]	432	[2]
Gains (Losses) on Sales of Assets	490		0
Other charges	128		175
Certain significant items [Member] | Earnings [Member]
Segment Reporting Information [Line Items]
Restructuring charges and implementation costs associated with cost-reduction initiatives, excluding acquisition-related costs	217		817
Certain legal matters, net	87		775
Certain asset impairment charges	396		412
Business Separation Costs	76		38
Other charges	16		25
Hisun Pfizer Pharmaceuticals Co. Ltd [Member] | Pfizer [Member]
Segment Reporting Information [Line Items]
Gains (Losses) on Sales of Assets	$ 490

[1] In the first quarter of 2013, primarily includes an $80 million insurance recovery related to a certain litigation matter. In the first quarter of 2012, primarily relates to a $450 million charge in connection with an agreement-in-principle to settle a lawsuit by Brigham Young University related to Celebrex (which was ultimately settled for that amount), and charges for hormone-replacement therapy litigation. For additional information, see Note 12. Commitments and Contingencies.

[2] In the first quarter of 2013, includes intangible asset impairment charges of $395 million, of which $394 million relates to developed technology, for use in the development of bone and cartilage, acquired in connection with our acquisition of Wyeth. The intangible asset impairment charges for 2013 reflect, among other things, updated commercial forecasts. The impairment charges for the first quarter of 2013 are associated with the following: Specialty Care ($394 million) and Animal Health (Zoetis) ($1 million).In the first quarter of 2012, includes intangible asset impairment charges of approximately $395 million, reflecting (i) $297 million of in-process research and development (IPR&D) assets that targeted autoimmune and inflammatory diseases, (ii) $45 million related to our Consumer Healthcare indefinite-lived brand, Robitussin, and (ii) $53 million of developed technology rights comprising the impairment of two assets. Substantially all of these impairment charges relate to intangible assets that were acquired as part of our acquisition of Wyeth. The intangible asset impairment charges reflect, among other things, the impact of new scientific findings for IPR&D and an increased competitive environment for Robitussin. The impairment charges for the first quarter of 2012 are associated with the following: Specialty Care ($316 million); Consumer Healthcare ($45 million); and Primary Care ($34 million)